Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Novartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by the US regulator last year – and has set a new action date of 1 ...

Sales growth was driven by continued strong performance from Entresto, Kesimpta, Kisqali, Cosentyx, and Leqvio. In Switzerland, Novartis shares were trading at 97.58 francs, up 4.03 percent.

Leqvio sales skyrocketed 83% to $223 million ... driven mainly by emerging growth markets. Novartis has a collaboration agreement with Roche RHHBY for Xolair. Novartis and Roche co-promote Xolair ...

Novartis forecasts further profit and sales ... cholesterol treatment Leqvio and multiple sclerosis medicine Kesimpta--offset a one-percentage-point hit from generic competition.

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...

Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per ...

Novartis has performed well in the previous ... Scemblix (chronic myeloid leukemia or CML), Pluvicto (prostate cancer), Leqvio (cholesterol) and Fabhalta (paroxysmal nocturnal hemoglobinuria ...

Last week, Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges ...